<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04668274</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol 202016</org_study_id>
    <secondary_id>1R44AG067907-01A1</secondary_id>
    <nct_id>NCT04668274</nct_id>
  </id_info>
  <brief_title>JOTROL PK, Safety, and Food Effect Assessment</brief_title>
  <official_title>A Phase 1 Study to Assess the Pharmacokinetics and Safety of Ascending Doses of JOTROL Oral Gelcaps in Healthy Subjects, and to Determine the Influence of Food</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marshall A. Hayward, Ph.D.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jupiter Orphan Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type of Study: Single Ascending Doses (SAD) Study&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  To characterize the pharmacokinetic (PK) profile of JOTROL (resveratrol) following oral&#xD;
           administration of SAD ranging from 200 mg up to a dose currently estimated at 1,000 mg,&#xD;
           in healthy subjects.&#xD;
&#xD;
        -  To evaluate the safety and tolerability of JOTROL&#xD;
&#xD;
        -  To evaluate the effect of food on the PK profile of JOTROL. Study Design: Phase I,&#xD;
           randomized, open-label, sequential SAD study with a food effect evaluation. Blood plasma&#xD;
           and urine samples will be assessed for resveratrol and key metabolite content.&#xD;
&#xD;
      Type of Control: No control Test Product: JOTROL (resveratrol) 100 mg resveratrol in 1000 mg&#xD;
      softgel capsule for oral administration Dosage Regimen: Planned dose levels of resveratrol:&#xD;
      200 mg, 500 mg, and 1,000 mg. Following completion of each dose level, PK, safety, and&#xD;
      tolerability data will be evaluated; dose levels may be adjusted.&#xD;
&#xD;
      Route of Administration: Oral gelcaps with water Number of Subjects: 24 subjects will be&#xD;
      included in Part 1; only 16 subjects, who completed Part 1, will be included in Part 2.&#xD;
&#xD;
      Subjects: Healthy, non-smoker, adult males or females, ≥ 18 and ≤ 75 years of age Study&#xD;
      Duration: Participation of each subject in this study should last approximately 1 to 1.5&#xD;
      months (for subjects participating in study Part 1 only) and 1.5 to 2 months (for subjects&#xD;
      participating in both study parts).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Ascending Dose pharmacokinetics, safety, and food effect</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by MedDRA version 23.1</measure>
    <time_frame>8 weeks</time_frame>
    <description>Number of Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>8 weeks</time_frame>
    <description>ng/ml resveratrol in blood plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curl e, AUC 0-t where t is time when resveratrol is undetectable</measure>
    <time_frame>8 weeks</time_frame>
    <description>ng*hr/ml resveratrol in blood plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum drug concentration (Tmax)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Time, hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Resveratrol elimination half life, T1/2 el</measure>
    <time_frame>8 weeks</time_frame>
    <description>Time, hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>concentration of resveratrol in urine</measure>
    <time_frame>8 weeks</time_frame>
    <description>ng/ml</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Safety</condition>
  <condition>Food-drug Interaction</condition>
  <arm_group>
    <arm_group_label>Initial Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First Low dose, initially 200 mg resveratrol as JOTROL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second (ascending) dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Second (presumed) intermediate dose estimated at 500 mg resveratrol as JOTROL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Third (ascending) dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Third (presumed) and highest dose estimated at 1000 mg resveratrol as JOTROL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Highest dose level (above) with a concomitant food evaluation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Third (presumed) and highest dose estimated at 1000 mg resveratrol as JOTROL administered in conjunction with a food effect evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg resveratrol as JOTROL</intervention_name>
    <description>Low (first) dose of single ascending dose study</description>
    <arm_group_label>Initial Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>500 mg resveratrol as JOTROL</intervention_name>
    <description>Second (intermediate) dose of single ascending dose study</description>
    <arm_group_label>Second (ascending) dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000 mg resveratrol as JOTROL</intervention_name>
    <description>Third (highest) dose of single ascending dose study</description>
    <arm_group_label>Third (ascending) dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000 mg resveratrol as JOTROL administered to assess influence of food</intervention_name>
    <description>1000 mg resveratrol as JOTROL administered to assess influence of food</description>
    <arm_group_label>Highest dose level (above) with a concomitant food evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Normal healthy male or female volunteers, non-smokers (no use of tobacco products&#xD;
             within 3 months prior to screening), ≥ 18 and ≤ 75 years of age, with BMI &gt; 18.5 and &lt;&#xD;
             30.0 kg/m 2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females&#xD;
&#xD;
          2. Healthy as defined by:&#xD;
&#xD;
               1. the absence of clinically significant illness and surgery within 4 weeks prior to&#xD;
                  dosing. Subjects vomiting within 24 hours predose will be carefully evaluated for&#xD;
                  upcoming illness/disease. Inclusion pre-dosing is at the discretion of the&#xD;
                  Investigator.&#xD;
&#xD;
               2. the absence of clinically significant history of neurological, endocrine,&#xD;
                  cardiovascular, respiratory, hematological, immunological, psychiatric,&#xD;
                  gastrointestinal, renal, hepatic, and metabolic disease as determined by the&#xD;
                  Investigator.&#xD;
&#xD;
          3. Females of childbearing potential who are sexually active with a male partner must be&#xD;
             willing to use one of the following acceptable contraceptive methods throughout the&#xD;
             study and for 30 days after the last study drug administration:&#xD;
&#xD;
               1. intra-uterine contraceptive device without hormone release system placed at least&#xD;
                  4 weeks prior to study drug administration;&#xD;
&#xD;
               2. male condom with intravaginally applied spermicide starting at least 21 days&#xD;
                  prior to study drug administration;&#xD;
&#xD;
               3. sterile male partner (vasectomized since at least 6 months).&#xD;
&#xD;
          4. Capable of consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any clinically significant abnormality at physical examination, clinically significant&#xD;
             abnormal laboratory test results or positive test for hepatitis B, hepatitis C, or HIV&#xD;
             found during medical screening.&#xD;
&#xD;
          2. Positive urine drug screen or urine cotinine test at screening.&#xD;
&#xD;
          3. History of allergic reactions to resveratrol, polyphenols, other related drugs, .&#xD;
&#xD;
             or to any excipient in the formulation&#xD;
&#xD;
          4. Positive pregnancy test at screening.&#xD;
&#xD;
          5. Breast-feeding subject.&#xD;
&#xD;
          6. Clinically significant ECG abnormalities or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 50 or&#xD;
             over 90 mmHg, or heart rate less than 50 or over 100 bpm) at screening.&#xD;
&#xD;
          7. History of significant alcohol abuse within 1 year prior to screening or regular use&#xD;
             of alcohol within 6 months prior to the screening visit (more than 14 units of alcohol&#xD;
             per week [1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol]).&#xD;
&#xD;
          8. History of significant drug abuse within 1 year prior to screening or use of soft&#xD;
             drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs&#xD;
             (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and&#xD;
             amphetamine derivatives) within 1 year prior to screening.&#xD;
&#xD;
          9. Use of resveratrol for a medical condition or in the context of another clinical trial&#xD;
             within a period of 30 days prior to the first dosing.&#xD;
&#xD;
         10. Participation in a clinical research study involving the administration of an&#xD;
             investigational or marketed drug or device within 30 days prior to the first dosing,&#xD;
             administration of a biological product in the context of a clinical research study&#xD;
             within 90 days prior to the first dosing, or concomitant participation in an&#xD;
             investigational study involving no drug or device administration.&#xD;
&#xD;
        Use of medications for the timeframes specified below, with the exception of medications&#xD;
        exempted by the Investigator on a case-by-case basis because they are judged unlikely to&#xD;
        affect the PK profile of the study drug or subject safety (e.g., topical drug products&#xD;
        without significant systemic absorption):&#xD;
&#xD;
          1. prescription medication within 14 days prior to the first dosing;&#xD;
&#xD;
          2. over-the-counter products and natural health products (including herbal remedies,&#xD;
             homeopathic and traditional medicines, probiotics, food supplements such as vitamins,&#xD;
             minerals, amino acids, essential fatty acids, and protein supplements used in sports)&#xD;
             within 14 days prior to the first dosing, with the exception of the occasional use of&#xD;
             acetaminophen (up to 2 g daily);&#xD;
&#xD;
          3. use of any drugs known to induce or inhibit hepatic drug metabolism within 30 days&#xD;
             prior to the first study drug administration, including St John's wort;&#xD;
&#xD;
          4. depot injection or an implant of any drug within 3 months prior to the first dosing.&#xD;
&#xD;
             12) Donation of plasma within 7 days prior to dosing. Donation or loss of blood&#xD;
             (excluding volume drawn at screening) of 50 mL to 499 mL of blood within 30 days, or&#xD;
             more than 499 mL within 56 days prior to the first dosing.&#xD;
&#xD;
             13) Any reason which, in the opinion of the Investigator, would prevent the subject&#xD;
             from participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Wyatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Syneos Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marshall A Hayward, Ph.D.</last_name>
    <phone>+1-908-507-3063</phone>
    <email>m.hayward@jupiterorphan.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fethia Benyebdri, Ph.D.</last_name>
    <phone>+1 514 485 7470</phone>
    <email>fethia.benyebdri@syneoshealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>inVentiv Health Clinical Research Services LLC, a Syneos Health company (&quot; Syneos Health &quot;) 1951 NW 7 th Avenue, Suite 450</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David J Wyatt, MD</last_name>
      <phone>305-547-5857</phone>
      <email>david.wyatt@syneoshealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Jupiter Orphan Therapeutics Inc.</investigator_affiliation>
    <investigator_full_name>Marshall A. Hayward, Ph.D.</investigator_full_name>
    <investigator_title>Chief Scientific Officer</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>resveratrol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 25, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT04668274/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 19, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT04668274/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT04668274/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

